Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells.
Chondroitin sulfate proteoglycan (CS-PG) expression is increased in response to CNS injury and limits the capacity for axonal regeneration. Previously we have shown that neurocan is one of the CS-PGs that is upregulated (Asher et al., 2000). Here we show that another member of the aggrecan family, versican, is also upregulated in response to CNS injury. Labeling of frozen sections 7 d after a unilateral knife lesion to the cerebral cortex revealed a clear increase in versican immunoreactivity around the lesion. Western blot analysis of extracts prepared from injured and uninjured tissue also revealed considerably more versican in the injured tissue extract. In vitro studies revealed versican to be a product of oligodendrocyte lineage cells (OLCs). Labeling was seen between the late A2B5-positive stage and the O1-positive pre-oligodendrocyte stage. Neither immature, bipolar A2B5-positive cells, nor differentiated, myelin-forming oligodendrocytes were labeled. The amount of versican in conditioned medium increased as these cells differentiated. Versican and tenascin-R colocalized in OLCs, and coimmunoprecipitation indicated that the two exist as a complex in oligodendrocyte-conditioned medium. Treatment of pre-oligodendrocytes with hyaluronidase led to the release of versican, indicating that its retention at the cell surface is dependent on hyaluronate (HA). In rat brain, approximately half of the versican is bound to hyaluronate. We also provide evidence of a role for CS-PGs in the axon growth-inhibitory properties of oligodendrocytes. Because large numbers of OLCs are recruited to CNS lesions, these results suggest that OLC-derived versican contributes to the inhospitable environment of the injured CNS.
Asher
Richard A
RA
Physiological Laboratory, University of Cambridge, Downing Site, Cambridge CB2 3EG, United Kingdom. raa24@cam.ac.uk
Morgenstern
Daniel A
DA
Shearer
Morven C
MC
Adcock
Kathryn H
KH
Pesheva
Penka
P
Fawcett
James W
JW
D000818:Animals; D001369:Axons / Q000187:drug effects / Q000502:physiology; D001930:Brain Injuries / Q000378:metabolism* / Q000473:pathology; D002454:Cell Differentiation / Q000502:physiology; D019070:Cell Lineage / Q000502:physiology; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism* / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006820:Hyaluronic Acid / Q000378:metabolism; D007150:Immunohistochemistry; D037181:Lectins, C-Type; D009836:Oligodendroglia / Q000166:cytology / Q000378:metabolism*; D011233:Precipitin Tests; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D019063:Tenascin / Q000378:metabolism; D015854:Up-Regulation / Q000502:physiology*; D053675:Versicans
D011508:Chondroitin Sulfate Proteoglycans; D017077:Culture Media, Conditioned; D037181:Lectins, C-Type; D019063:Tenascin; C508324:Vcan protein, rat; D053675:Versicans; C074638:tenascin R; D006820:Hyaluronic Acid